2-Diethylamino-butanol-(1) | 61940-73-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Diethylamino-butanol-(1)
• 英文别名: 2-(Diethylamino)butan-1-ol
• CAS: 61940-73-6
• 化学式: C₈H₁₉NO
• mdl: MFCD19686256
• 分子量: 145.245
• InChiKey: HZDMXYFSFGUCNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Diethylamino-butanol-(1) 生成 diethyl-(1-hydroxymethyl-propyl)-methyl-ammonium; iodide
  参考文献：
  名称：

  Muths, Bulletin de la Societe Chimique de France, 1955, p. 1098

  摘要：

  DOI：
• 作为产物：
  描述：

  2-diethylamino-butyric acid ethyl ester 在 乙醇 、 sodium 作用下， 生成 2-Diethylamino-butanol-(1)
  参考文献：
  名称：

  Rajner; Cerkovnikov; Stern, Archiv der Pharmazie, 1943, p. 81

  摘要：

  DOI：

文献信息

• Method for Crystalline Preparing Metalloaluminophosphate (MeAPO) Molecular Sieves
  申请人：Nesterenko Nikolai

  公开号：US20110196183A1

  公开（公告）日：2011-08-11

  The invention relates to a process for obtaining a metalloaluminophosphate (MeAPO) molecular sieve comprising the following steps in the order given: a) providing a homogeneous solution containing sources of at least 2 of the following: aluminium (Al), phosphorous (P), metal (Me); b) adding a first MeAPO molecular sieve to the solution and modifying the pH before and/or after the addition of the first MeAPO molecular sieve to obtain an amorphous precursor; c) separating the amorphous precursor from the water; d) optionally washing and drying at a temperature below 450° C. of the amorphous precursor; e) contacting the amorphous precursor with an organic template-containing aqueous solution and with a source of Al, P or Me, which is not already present in step (a), optionally additional sources of Al and/or P and/or Me and optionally in the presence of aliphatic alcohols; f) performing a crystallization of the amorphous precursor under autogeneous conditions so as to increase the concentration of the crystalline molecular sieve in respect to the initial precursor and so as to obtain a second MeAPO molecular sieve.

  该发明涉及一种获得金属铝磷酸盐（MeAPO）分子筛的工艺，包括按照以下顺序进行的以下步骤：a）提供含有至少以下2种来源的均匀溶液：铝（Al）、磷（P）、金属（Me）；b）向溶液中添加第一种MeAPO分子筛，并在添加第一种MeAPO分子筛之前和/或之后修改pH以获得无定形前体；c）将无定形前体与水分离；d）可选地在无定形前体的温度低于450°C时进行洗涤和干燥；e）将无定形前体与含有有机模板的水溶液接触，并与Al、P或Me的来源接触，该来源在步骤（a）中尚未存在，可选地还有Al和/或P和/或Me的附加来源，并且可选地在脂肪醇的存在下；f）在自发条件下对无定形前体进行结晶，以增加晶体分子筛的浓度相对于初始前体，并获得第二种MeAPO分子筛。
• Method for Preparing Crystalline Metalloaluminophosphate (MeAPO) Molecular Sieve from Amorphous Materials
  申请人：Nesterenko Nikolai

  公开号：US20110295050A1

  公开（公告）日：2011-12-01

  A process for obtaining a metalloaluminophosphate (MeAPO) molecular sieve comprising the following steps in the order given: a). providing an aqueous solution containing sources of at least 2 of the following: Metals (Me), Al and P; b). co-precipitating an amorphous precursor of the molecular sieve from the solution by changing the solution's pH, followed by separating the amorphous precursor from the water, optionally including formulation; c). optionally washing and drying at a temperature below 450° C. of the amorphous precursor; d). contacting the amorphous precursor with a template-containing aqueous solution and with a source of Al, P or Me, which is not already present in step (a) and optionally additional sources of Al and/or P and/or Me; and e). partially crystallising the molecular sieve under autogeneous conditions so that 5 to 90% by weight of the amorphous precursor crystallises.

  获得金属铝磷酸盐（MeAPO）分子筛的过程包括按照给定顺序进行以下步骤：a)。提供含有至少以下2种物质来源的水溶液：金属（Me）、铝和磷；b)。通过改变溶液的pH值，共沉淀分子筛的无定形前驱体，然后将无定形前驱体与水分离，可包括配方；c)。可选地将无定形前驱体在低于450°C的温度下洗涤和干燥；d)。将无定形前驱体与含有模板的水溶液以及铝、磷或Me的来源接触，这些来源不在步骤（a）中，并可选地包括额外的铝和/或磷和/或Me来源；e)。在自发条件下部分结晶化分子筛，使无定形前驱体的5至90%的重量结晶。
• Process for Obtaining Catalyst Composites MeAPO and Their Use in Conversion of Organics to Olefins
  申请人：TOTAL PETROCHEMICALS RESEARCH FELUY

  公开号：US20130317269A1

  公开（公告）日：2013-11-28

  A mixture can include 0.01 to 30 weight % of a medium or large pore crystalline silicoaluminate, silicoaluminophosphate materials, or silicoaluminate mesoporous molecular sieves (A), and 99.99 to 70 weight % of a MeAPO molecular sieve. The mixture can be included in a catalyst. An XTO process can include contacting an oxygen-containing, halogenide-containing, or sulphur-containing organic feedstock with the catalyst under conditions effective to convert the organic feedstock to olefin products. A combined XTO and OCP process can include contacting the organic feedstock with the catalyst at conditions effective to convert at least a portion of the organic feedstock to form an XTO reactor effluent including light olefins and a heavy hydrocarbon fraction, separating the light olefins from the heavy hydrocarbon fraction, and contacting the heavy hydrocarbon fraction in an OCP reactor at conditions effective to convert at least a portion of the heavy hydrocarbon fraction to light olefins.

  混合物可以包含0.01至30重量％的中孔或大孔结晶硅铝酸盐、硅铝磷酸盐材料或硅铝酸盐介孔分子筛（A），以及99.99至70重量％的MeAPO分子筛。该混合物可以包含在催化剂中。XTO过程可以包括将含氧、含卤素或含硫有机原料与催化剂接触，以有效地将有机原料转化为烯烃产品。联合XTO和OCP过程可以包括在有效条件下将有机原料与催化剂接触，以将至少部分有机原料转化为形成包括轻烯烃和重烃分馏物的XTO反应器流出物，将轻烯烃与重烃分馏物分离，并在OCP反应器中以有效条件将至少部分重烃分馏物转化为轻烯烃。
• MTO process based on MeAPO molecular sieves combined with an OCP process to make olefins
  申请人：TOTAL PETROCHEMICALS RESEARCH FELUY

  公开号：EP1970361A1

  公开（公告）日：2008-09-17

  The present invention relates to a process to make light olefins from an oxygen-containing, halogenide-containing or sulphur-containing organic feedstock comprising: contacting said oxygen-containing, halogenide-containing or sulphur-containing organic feedstock in a primary reactor with a catalyst made of a metalloaluminophosphate (MeAPO) molecular sieve with lamellar crystal morphology at conditions effective to convert at least a portion of the feedstock to form a first reactor effluent comprising light olefins and a heavy hydrocarbon fraction; separating said light olefins from said heavy hydrocarbon fraction; contacting said heavy hydrocarbon fraction in a second reactor at conditions effective to convert at least a portion of said heavy hydrocarbon fraction to light olefins; wherein said MeAPO either has an empirical chemical composition on an anhydrous basis, after synthesis and calcination, expressed by the formula HxMey,AlzPkO2 in which, y+z+k=1 x<=y y has a value ranging from 0.0008 to 0.4 and advantageously from 0.005 to 0.18 z has a value ranging from 0.25 to 0.67 and advantageously from 0.38 to 0.55 k has a value ranging from 0.2 to 0.67 and advantageously from 0.36 to 0.54 said molecular sieve having predominantly a plate crystal morphology in which the width (W) and the thickness (T) are such as: W/T is >= 10 and advantageously ranges from 10 to 100, or wherein said MeAPO has been prepared by a method comprising: a) forming a reaction mixture containing a texture influencing agent (TIA), an organic templating agent (TEMP), at least a reactive inorganic source of MeO2 insoluble in the TIA, reactive sources of Al2O3 and P2O5, b) crystallizing the above reaction mixture thus formed until crystals of the metalloaluminophosphate are formed, c) recovering a solid reaction product, d) washing it with water to remove the TIA and e) calcinating it to remove the organic template.

  本发明涉及一种从含氧、含卤或含硫有机原料制备轻烯烃的方法，包括：在主反应器中，将所述含氧、含卤或含硫有机原料与一种金属铝磷酸盐（MeAPO）分子筛催化剂接触，以有效条件转化至少部分原料，形成含轻烯烃和重烃分数的第一反应器流出物；将轻烯烃与重烃分离；在第二反应器中，将重烃分数在有效条件下转化至少部分为轻烯烃；其中所述MeAPO在无水基础上具有经验化学组成，经合成和焙烧后，用下式表示：HxMey,AlzPkO2，其中，y+z+k=1，x<=y，y的值范围为0.0008至0.4，优选为0.005至0.18，z的值范围为0.25至0.67，优选为0.38至0.55，k的值范围为0.2至0.67，优选为0.36至0.54，所述分子筛主要具有板状晶体形态，其宽度（W）和厚度（T）满足以下条件：W/T >= 10，优选范围为10至100；或者所述MeAPO是通过以下方法制备的：a)形成含有纹理影响剂（TIA）、有机模板剂（TEMP）、至少一种不溶于TIA的MeO2的反应性无机源、Al2O3和P2O5的反应性源的反应混合物，b)结晶上述形成的反应混合物，直至形成金属铝磷酸盐晶体，c)回收固体反应产物，d)用水洗涤以去除TIA，e)焙烧以去除有机模板。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ZENECA LIMITED

  公开号：WO1996033980A1

  公开（公告）日：1996-10-31

  (EN) The invention concerns quinazoline derivatives of the formula (I) wherein n is 1, 2 or 3 and each R2 is independently halogeno, trifluoromethyl or (1-4C)alkyl; R3 is (1-4C)alkoxy; and R1 is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy, imidazol-1-yl-(2-4C)alkoxy, di-[(1-4C)alkoxy-(2-4C)alkoxyl]amino-(2-4C)alkoxy, thiamorpholino-(2-4C)alkoxy, 1-oxothiamorpholino-(2-4C)alkoxy or 1,1-dioxothiamorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R1 substituents comprising a CH2 (methylene) group which is not attached to a N or O atom optionally bears on said CH2 group a hydroxy substituent; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.(FR) L'invention concerne des dérivés de quinazoline de formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule (I), n vaut 1, 2 ou 3 et chaque R2 représente séparément halogéno, trifluorométhyle ou alkyle (1-4C); R3 représente alcoxy (1-4C); et R1 représente di[alkyl(1-4C)]amino-alcoxy(2-4C), pyrrolidin-1-yl-alcoxy(2-4C), pipéridino-alcoxy(2-4C), morpholino-alcoxy(2-4C), pipérazin-1-yl-alcoxy(2-4C), 4-alkylpipérazin(1-4C)-1-yl-alcoxy(2-4C), imidazol-1-yl-alcoxy(2-4C), di[alcoxy(1-4C)-alkyl(2-4C)]amino-alcoxy(2-4C), thiamorpholino-alcoxy(2-4C), 1-oxothiamorpholino-alcoxy(2-4C) ou 1,1-dioxothiamorpholino-alcoxy(2-4C), et dans laquelle les substituants de R1 susmentionnés comprenant un groupe CH¿2(méthylène) qui n'est pas attaché à un atome N ou O porte éventuellement sur ledit groupe CH2 un substituant hydroxy. L'invention porte aussi sur des procédés de préparation desdits composés, des compositions pharmaceutiques les contenant et l'utilisation des propriétés inhibitrices de la tyrosine-kinase réceptrice du composé dans le traitement de maladies prolifératives telles que le cancer.

  本发明涉及式(I)的喹唑啉衍生物，其中n为1、2或3，每个R2独立地为卤素、三氟甲基或(1-4C)烷基；R3为(1-4C)烷氧基；R1为双[(1-4C)烷基]氨基-(2-4C)烷氧基、吡咯烷-1-基-(2-4C)烷氧基、哌啶-(2-4C)烷氧基、吗啉-(2-4C)烷氧基、哌嗪-1-基-(2-4C)烷氧基、4-(1-4C)烷基哌嗪-1-基-(2-4C)烷氧基、咪唑-1-基-(2-4C)烷氧基、双[(1-4C)烷氧基-(2-4C)烷氧基]氨基-(2-4C)烷氧基、硫代吗啉-(2-4C)烷氧基、1-氧代硫代吗啉-(2-4C)烷氧基或1,1-二氧代硫代吗啉-(2-4C)烷氧基，其中上述任何一个具有未连接到N或O原子的CH2(亚甲基)基的R1取代基可选择在该CH2基上具有一个羟基取代基；或其药学上可接受的盐；以及它们的制备方法、包含它们的制药组合物和利用该化合物的受体酪氨酸激酶抑制性质治疗增殖性疾病如癌症的用途。

表征谱图